No. 94

April 2014

Headline News Innovation and Development

Applied Technology

Basic Science

Cooperation between CAS and Local Authorities

Bioscience International Cooperation Brief News Geoscience Activities of CAS Leaders
Innovation and Development

Breakthrough in Processing Technique of Large Aperture Mirror

The development and production of BZPMJ700 standard plane mirror was completed by Aupu Photo-electric Co. Ltd. on March 25, with accuracy as following, PV is 0.187, rms 0.018λ、power 0.003λ. The BZPMJ700 standard mirror consists of two parts: the plane reflection mirror and the two dimention precision supporter. The accuracy of plane mirror effective aperture reached PV=0.187λ、rms=0.018λ、power=0.003λ(λ=632.8nm). Such kind of mirrors and relevant series of mirrors with different sizes and categories can be produced with processing period of six months.

Peptide-based YAP Inhibitor Brings Hope for Gastric Cancer Treatment

Gastric cancer is characteristic of poor prognosis and high death rate, making it the second most common cause of cancer-related death worldwide. Hippo pathway, as an emerging significant player in tumorigenesis, has recently been attracting increasing attention for the development of new anti-cancer drugs. In Hippo pathway, YAP can bind TEADs to form a “hybrid” transcription factor and therefore regulate growth-related genes. In contrast to targeting upstream regulators, inhibition of YAP, the ultimate downstream effector of Hippo signaling, may provide a more effective and direct way to redress the Hippo pathway. Jiao Shi and her colleagues from a research group led by Prof. Zhou Zhaocai at the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, CAS identified VGLL4 as a clinical relevant natural antagonist of YAP, and importantly its TDU domain is sufficient for YAP inhibition by directly competing with YAP for binding TEADs. These findings combined with a 3D structural analysis of the VGLL4-TEAD complex, allowed for the development of a peptide-based YAP inhibitor. This peptide potently suppresses gastric tumor growth, providing an opportunity for treating gastric cancer which currently lacks effective treatment options. Moreover, cancer cells with an elevated ratio of YAP to VGLL4 appear to be more sensitive to this type of peptide treatment. Such therapeutic strategy may also be extended to other cancer types driven by hyperactive YAP. This study entitled “A Peptide Mimicking VGLL4 Function Acts as a YAP Antagonist Therapy against Gastric Cancer” was published online in Cancer Cell on Feb. 10, 2014. This work was done in collaboration with Prof. Zhang Lei and Prof. Ji Hongbin.

Other Issues
Ninety-third Issue (February 2014)
Ninety-second Issue (December 2013)
Ninety-first Issue (October 2013)
Ninetieth Issue (August 2013)
Eighty-ninth Issue (June 2013)
Eighty-eighth Issue (April 2013)
Eighty-sixth Issue (February 2013)
Eighty-fifth Issue (December 2012)
Eighty-forth Issue (October 2012)
Eighty-third Issue (August 2012)
Eighty-second Issue (June 2012)
Eighty-first Issue (April 2012)
Eightieth Issue (February 2012)
Seventy-ninth Issue (December 2011)
Seventy-eighth Issue (October 2011)
Seventy-seventh Issue (August 2011)
Seventy-sixth Issue (June 2011)
Seventy-fifth Issue (April 2011)
Seventy-forth Issue (February 2011)
Seventy-third Issue (December 2010)
Seventy-second Issue (October 2010)
Seventy-first Issue (August 2010)
Seventieth Issue (June 2010)
Sixty-nineth Issue (April 2010)
Sixty-eighth Issue (February 2010)

Sixty-seventh Issue (December 2010)

Sixty-sixth Issue (October 2009)
Sixty-fifth Issue (August 2009)
Sixty-fourth Issue (June 2009)
Sixty-third Issue (April 2009)
Sixty-second Issue (February 2009)
Sixty-first Issue (December 2008)
Sixtieth Issue (October 2008)
Fifty-nineth Issue (August 2008)
Fifty-eighth Issue (June 2008)
Fifty-seventh Issue (April 2008)
Fifty-sixth Issue (February 2008)

copyright © 1998-2015
CAS Newsletter Editorial Board: 52, Sanlihe Road, Beijing 100864, CHINA